FDA Grants Third Approval Under the National Priority Voucher Program
WHY IT MATTERS
Patients with relapsed or refractory multiple myeloma now have a new treatment option that combines two drugs shown to work together, potentially offering better outcomes for those who have exhausted earlier treatment lines.
The FDA has approved a new two-drug combination called Tec-Dara to treat multiple myeloma, a blood cancer that has come back or stopped responding to previous treatments. This approval is special because it was fast-tracked through a program that rewards companies for developing medicines for serious diseases. The combination uses two drugs that work together to help patients whose cancer has already been treated at least once before.
The U.S. Food and Drug Administration today approved teclistamab in combination with daratumumab hyaluronidase-fihj, Tec-Dara, to treat adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
ASK YOUR DOCTOR
If you have relapsed or refractory multiple myeloma and have received prior treatment, ask your oncologist at your next appointment whether Tec-Dara might be appropriate for your specific situation.